Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.17
- Piotroski Score 2.00
- Grade Market Perform
- Symbol (NGM)
- Company NGM Biopharmaceuticals, Inc.
- Price $1.54
- Changes Percentage (-1.28%)
- Change -$0.02
- Day Low $1.54
- Day High $1.57
- Year High $4.69
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 05/01/2024
- Fiscal Year End N/A
- Average Stock Price Target $16.50
- High Stock Price Target $29.00
- Low Stock Price Target $4.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.73
- Trailing P/E Ratio -0.89017341040462
- Forward P/E Ratio -0.89017341040462
- P/E Growth -0.89017341040462
- Net Income $-142,375,000
Income Statement
Quarterly
Annual
Latest News of NGM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Dem kingmaker George Soros' son Alex hosts Tim Walz in his fancy NYC...
Left-wing donor Alex Soros recently hosted Tim Walz, Kamala Harris' running mate, in New York City. Alex, son of billionaire George Soros, shared photos with Walz on social media. He is known for supp...
By New York Post | 3 days ago -
Sudan's jailed former strongman Omar al-Bashir is taken to a hospital in the north for better care
Former Sudanese President Omar al-Bashir, ousted after 30 years, has been moved to a medical facility due to health issues. His lawyer mentioned his need for regular care, while also stating that his ...
By AP NEWS | 3 days ago -
Trump touts European 'strongman' as close ally during presidential debate: Who is Viktor Orban?
Former President Trump highlighted his foreign policy achievements during the debate, emphasizing relationships with world leaders like Hungary's Viktor Orban. Orban praised Trump's peace efforts and ...
By Fox News | 2 weeks ago